Vadadustat

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Vadadustat is an onp drug in the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor class catalogued in DrugCentral. It was first approved by the PMDA in 2020. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Organic Anion Transporter 3 Inhibitors. DrugCentral lists 11 molecular targets, including EGLN3, EGLN2 and EGLN1. Recorded indications include Anemia in chronic kidney disease and Anemia of renal disease.

• Approval status: onp (first approved 2020 by the PMDA).
• Drug class: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors; Organic Anion Transporter 3 Inhibitors.
• Molecular targets: EGLN3, EGLN2, EGLN1 and A085R (11 listed in DrugCentral).
• Indications: Anemia in chronic kidney disease and Anemia of renal disease.
• ATC code: B03XA08 (Other antianemic preparations).
• Molecular formula: C14H11ClN2O4; molecular weight 306.70 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Anemia in chronic kidney disease
• Anemia of renal disease

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors; Organic Anion Transporter 3 Inhibitors
• Established pharmacologic class: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor

Molecular targets (11)

Target	Gene	Action	Activity
Egl nine homolog 3	EGLN3	inhibitor	IC50 8.12
Egl nine homolog 2	EGLN2	inhibitor	IC50 7.93
Egl nine homolog 1	EGLN1	inhibitor	IC50 7.81
Prolyl 4-hydroxylase	A085R	unknown	Ki 6.55
Gamma-butyrobetaine dioxygenase	BBOX1	unknown	IC50 6.55
Prolyl 3-hydroxylase OGFOD1	OGFOD1	unknown	IC50 5.85
Aspartyl/asparaginyl beta-hydroxylase	ASPH	unknown	IC50 5.36
Methylcytosine dioxygenase TET2	TET2	unknown	IC50 5.30
Vascular endothelial growth factor receptor 1	FLT1	unknown	EC50 5.12
Vascular endothelial growth factor A	VEGFA	unknown	EC50 5.12
Hypoxia-inducible factor 1-alpha inhibitor	HIF1AN	unknown	IC50 4.54

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2023-04-24	EMA	—	AKEBIA EUROPE LIMITED
2020-06-29	PMDA	—	Mitsubishi Tanabe Pharma

ATC classification

ATC code	Therapeutic hierarchy
B03XA08	BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › OTHER ANTIANEMIC PREPARATIONS › Other antianemic preparations

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Marasmus	96.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vadadustat is on its molecule page.

• Molecular formula: C₁₄H₁₁ClN₂O₄
• Molecular weight: 306.70 g/mol
• CAS number: 1000025-07-9
• InChIKey: JGRXMPYUTJLTKT-UHFFFAOYSA-N
• PubChem CID: 23634441

C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vadadustat used for?

DrugCentral lists the following indications for Vadadustat: Anemia in chronic kidney disease and Anemia of renal disease.

How does Vadadustat work?

Vadadustat is classified as Breast Cancer Resistance Protein Inhibitors, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Organic Anion Transporter 3 Inhibitors; its molecular targets in DrugCentral include EGLN3 (inhibitor), EGLN2 (inhibitor), EGLN1 (inhibitor) and A085R.

When was Vadadustat first approved?

Vadadustat was first approved by the PMDA in 2020.

What drug class does Vadadustat belong to?

Vadadustat is in the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor class.

What is the chemical formula of Vadadustat?

Vadadustat has the molecular formula C14H11ClN2O4 and a molecular weight of 306.70 g/mol.

Sources

• DrugCentral drug card 5420 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3646221 — compound record and bioactivity
• PubChem CID 23634441 — chemical identifiers
• DrugBank DB12255 — drug record
• FDA UNII I60W9520VV — substance identity
• UniProt Q9H6Z9 (EGLN3) — target protein
• UniProt Q96KS0 (EGLN2) — target protein
• UniProt Q9GZT9 (EGLN1) — target protein
• UniProt O75936 (BBOX1) — target protein
• UniProt Q8N543 (OGFOD1) — target protein
• UniProt Q12797 (ASPH) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.